Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mirum Pharmaceuticals ( (MIRM) ) has issued an update.
On November 17, 2025, Mirum Pharmaceuticals received a Paragraph IV Certification Notice from Sandoz, indicating Sandoz’s intent to produce a generic version of Livmarli. Mirum plans to defend its patents vigorously by filing a patent infringement suit against Sandoz, which could delay the FDA’s approval of the generic drug for up to 30 months.
The most recent analyst rating on (MIRM) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.
Spark’s Take on MIRM Stock
According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.
Mirum Pharmaceuticals’ overall stock score is driven by strong earnings call results, highlighting significant revenue growth and positive net income. However, financial performance concerns, particularly profitability and high leverage, weigh heavily on the score. Technical analysis and valuation also present challenges, with bearish momentum and a negative P/E ratio.
To see Spark’s full report on MIRM stock, click here.
More about Mirum Pharmaceuticals
Mirum Pharmaceuticals operates in the pharmaceutical industry, focusing on developing treatments for rare liver diseases. Its primary product, Livmarli (maralixibat), is a medication aimed at addressing these conditions.
Average Trading Volume: 708,426
Technical Sentiment Signal: Buy
Current Market Cap: $3.67B
See more data about MIRM stock on TipRanks’ Stock Analysis page.